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Lipid transfer inhibitor protein (apolipoprotein F)
concentration in normolipidemic and
hyperlipidemic subjects
Richard E. Morton,1 Hannah M. Gnizak, Diane J. Greene, Kyung-Hyun Cho,2
and Victor M. Paromov3
Department of Cell Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195

Abstract Lipid transfer inhibitor protein (LTIP) is an
important regulator of cholesteryl ester transfer protein
function. We report the development of an immunoassay
for LTIP and its use to quantify LTIP in plasma of varying
lipid contents. A rabbit antibody against bacterially produced recombinant LTIP detected two LTIP isoforms in
plasma differing in carbohydrate content. This antibody was
used in a competitive, enzyme-linked immunoassay that uses
partially purified LTIP bound to microtiter plates. To
optimize LTIP immunoreactivity, plasma samples required
preincubation in 1% Tween-20 and 0.5% Nonidet P-40. In
normolipidemic plasma, LTIP averaged 83.5 mg/ml. LTIP
was 31% higher in males than in females. LTIP was
positively associated with HDL cholesterol in normolipidemic males but not in females. In hypertriglyceridemic
males, LTIP was only 56% of control values, whereas in
hypertriglyceridemic females, LTIP tended to increase.
Additionally, in males with normal cholesterol and triglyceride (TG) < 200 mg/dl, LTIP varied inversely with plasma
TG. Overall, we have confirmed the negative association
between plasma TG levels and LTIP previously suggested
by a small data set, but now we demonstrate that this effect
is seen only in males. The mechanisms underlying this
gender-specific response to TG, and why LTIP and HDL
levels correlate in males but not in females, remain to be
determined.—Morton, R. E., H. M. Gnizak, D. J. Greene,
K-H. Cho, and V. M. Paromov. Lipid transfer inhibitor protein
(apolipoprotein F) concentration in normolipidemic and
hyperlipidemic subjects. J. Lipid Res. 2008. 49: 127–135.
Supplementary key words cholesteryl ester transfer protein & cholesteryl ester transfer protein inhibition & glycoprotein & enzyme-linked
immunosorbent assay

In plasma, cholesteryl ester transfer protein (CETP) mediates the net transfer of cholesteryl ester (CE) from LDL
and HDL to VLDL in return for triglyceride (TG) (1, 2).
Several lines of evidence suggest that lipid transfer
inhibitor protein (LTIP), also known as apolipoprotein F
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(3), alters this process and influences the capacity of CETP
to remodel lipoproteins. We have shown that among normolipidemic subjects, LTIP activity levels in whole plasma
associate negatively with the rate of lipid transfer between
VLDL and LDL (4). The addition of exogenous LTIP to
native plasma reduces the participation of LDL in lipid
transfer events but leads to a dose-dependent increase in
the efflux of CE from HDL to VLDL, resulting in HDLs
that are markedly better substrates for lecithin:cholesterol
acyltransferase (5). We have proposed that this increased
CETP activity on HDL happens because plasma TG, not
CETP, is rate-limiting for net lipid transfer in normal
plasma (6, 7). Thus, in the presence of LTIP, less VLDL
TG is expended by transfer to LDL, allowing the transfer
from VLDL to HDL to be increased.
We substantiated the foregoing observations through
studies of patients undergoing continuous ambulatory
peritoneal dialysis, who have very low LTIP activity (8). In
these patients, the 2-fold preference of CETP for HDL as a
lipid donor (compared with LDL) seen in normal plasma
is absent. In separate studies, we determined that CETP
actually displays no preference for total HDL as a substrate
in assays with isolated lipoproteins; however, the addition
of plasma levels of LTIP to these assays completely reconstitutes the 2-fold preference of CETP for HDL that
exists in native plasma (9). These data strongly suggest that
the enhanced lipid transfer from HDL in control plasma,
which generally has been attributed to a preferential
interaction between CETP and HDL, is the consequence
of LTIP activity. Recently, we reported that this stimula-
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protein; TG, triglyceride.
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tion of CETP-mediated lipid transfer from HDL by LTIP
occurs almost exclusively on HDL3 particles (10). In aggregate, these data show that LTIP can alter the overall
pattern of lipid transfer events between lipoproteins mediated by CETP.
Despite its potentially important role as a regulator of
CETP function, the physiological concentration of LTIP in
normolipidemic subjects is not known, nor is it known how
these levels may vary in various hyperlipidemic states. We
previously observed in a small study that LTIP activity is
increased in hyperlipidemia and that this increase is mitigated when plasma TG levels are high (11). In this study,
we report the development of an immunoassay for LTIP
quantification and its application to plasma of varying
lipoprotein contents. We have used this assay to further
examine the relationship between LTIP and plasma TG
levels in a larger, better defined patient population. We
observed that LTIP levels, and their change in the presence of hyperlipidemia, are gender-specific.

METHODS

LTIP was produced in rabbits using this mixture of LTIP-GST
proteins (Biosynthesis, Inc., Lewisville, TX).

Expression of recombinant LTIP in Sf21cells
The purified EcoRI fragment of LTIP cDNA, as described
above, was ligated into pBlueBacHis2B (Invitrogen). Correct orientation and sequence were confirmed by PCR. This construct
was inserted into Bac-N-Blue AcMNPV DNA by homologous
recombination, and the resulting recombinant virus was purified
by plaque assay and amplified to obtain P3 high-titer stocks. Sf21
cells were seeded into 500 ml spinner flasks and grown to 50%
confluence. Cells were infected with recombinant baculovirus
and harvested after 4 days. After low-speed centrifugation to remove cells and debris, conditioned medium was stored at 280jC.
Recombinant lipid transfer inhibitor protein (rLTIP) was
precipitated from conditioned medium by ammonium sulfate
(40% final saturation). After 5 h at 4jC, the medium was centrifuged and the pellet was resuspended in PBS followed by
extensive dialysis against PBS. The ammonium sulfate fraction
was adjusted to 6 M guanidine-HCl, 10 mM imidazole, and
20 mM b-mercaptoethanol, pH 7.4, and incubated with Ni-NTA
(Qiagen, Inc., Valencia, CA) at 25jC for 5 h. The agarose matrix was packed into a column and washed extensively with 8 M
urea, 10 mM imidazole, and 20 mM b-mercaptoethanol in
PBS. rLTIP was eluted with the same buffer adjusted to contain
100 mM imidazole.

Materials
N-Acetylneuraminidase (NANase) and O-glycanase were purchased from Glyko, Inc. (Novato, CA). Human LDL and HDL
were isolated by sequential ultracentrifugation (12). LDL was
radiolabeled with [3H]CE by a dispersion transfer method (13).
CETP and LTIP were partially purified from frozen plasma as
described previously (14). CETP and LTIP activities were
measured by their ability to stimulate CE transfer from LDL to
HDL and to inhibit CETP-mediated CE transfer from LDL to
HDL, respectively, as described previously (13, 15, 16).

Expression of recombinant LTIP in bacteria
and antibody production
Human LTIP (apolipoprotein F), originally cloned as described and inserted into pCR3.1 (3), was excised with EcoRI and
the purified fragment was ligated into pGEX-4T-1 (GE Healthcare, Piscataway, NJ). After transformation of SoloPack Gold
Escherichia coli (Stratagene, La Jolla, CA) with this construct,
proper insert orientation was confirmed by BamHI and XbaI
restriction. For fusion protein production, BL21(DE3)pLysS
E. coli (Novagen, Madison, WI) was transformed with this construct. Log-phase cells were grown in broth containing ampicillin
(100 mg/ml) and 2% glucose. After a 2 h induction with 1 mM
isopropylthio-b-galactoside, bacteria were harvested by centrifugation. The cell pellet was resuspended in PBS containing a
protease inhibitor cocktail (Roche), sonicated, and incubated
for 30 min at 4jC after the addition of 1% Triton X-100. After
centrifugation, the supernatant was incubated with glutathioneSepharose, the matrix was washed extensively with PBS, and then
LTIP-GST (for glutathione S-transferase) fusion protein was
eluted with 50 mM Tris-HCl and 10 mM reduced glutathione,
pH 8.0. As determined from Coomassie blue-stained electrophoretic gels, three protein bands of similar intensity were present: a
band of 44.3 kDa, consistent with intact LTIP-GST fusion protein,
and bands at 28.5 and 26 kDa. All three bands were reactive with
anti-GST antibody, indicating that the two smaller bands are
degradation products, which, because they retain the ability to
bind to glutathione-Sepharose, presumably contain GST and
only a portion of the LTIP sequence. Polyclonal antibody against
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Western blots
Samples containing 63 mM Tris-HCl, 2% SDS, 10% glycerol, 5% b-mercaptoethanol, and 0.5 mg/ml bromophenyl
blue, pH 8.3, were heated for 5 min at 100jC and then applied to 7.5% or 4–20% polyacrylamide gels (Cambrex
BioScience, Rockland, ME). Subsequently, proteins were electrotransferred to polyvinylidene fluoride membranes (17),
and membranes were blocked with 5% dry milk and 1% calf
serum in PBS and then reacted with the indicated antibody in
the same buffer. Bound primary antibodies were reacted with
the appropriate horseradish peroxidase-conjugated secondary
antibody (1:1,000) (Calbiochem, San Diego, CA), and complexes were detected by enhanced chemiluminesence-mediated
(GE Healthcare) autoradiography.

LTIP immunoassay (ELISA)
Partially purified LTIP was diluted in 15 mM Na2CO3 and
0.02% NaN3, pH 9.6, binding buffer to yield 6 mg protein/ml.
Diluted LTIP (100 ml) was added to each well of 96-well
microtiter plates (Nunc Maxisorp; Nalge Nunc International,
Rochester, NY) and incubated for 4 h. This and all subsequent
steps were performed at room temperature. Wells were washed
twice with PBS and blocked with 200 ml of 3% BSA, 2 mM EDTA,
and 0.02% NaN3 in PBS overnight. Samples were diluted and
adjusted to contain 1% Tween-20 in PBS or 1% Tween-20 and
0.5% Nonidet P-40 in PBS, as indicated, and incubated overnight.
The next day, 200 ml of anti-LTIP antiserum (1:500 dilution in
1% BSA and 0.02% EDTA in PBS) was combined with 200 ml of
treated samples, and 100 ml aliquots were added to each of three
wells. This resulted in a final detergent concentration of 0.5%
Tween-20 and 0.25% Nonidet P-40 (when present). Plates were
incubated for 3 h, then washed four times with PBS containing
0.05% Tween-20. Goat anti-rabbit IgG horseradish peroxidase
conjugate (1:2,000 dilution in 1% BSA and 0.02% EDTA in PBS)
was added (100 ml/well) and reacted for 2 h. After three washes
with PBS containing 0.05% Tween-20 and three washes with PBS
alone, wells received 100 ml of o-phenylenediamine substrate solution (1 mg of o-phenylenediamine in 25 mM citric acid and

50 mM Na2HPO4 containing 0.03% H2O2). Color development
was stopped with 50 ml of 10 N H2SO4, and the absorbance at
490 nm was read.
Because we have been unable to isolate sufficient pure LTIP
from plasma or from cells expressing rLTIP, we developed an
alternative strategy to calibrate the ELISA. rLTIP was partially
purified (?80% pure as assessed by silver staining of PAGE gels)
from baculovirus-infected Sf21 cells as described above. This
construct contains a HisG tag epitope identical to that contained
in Positope (Invitrogen). Positope is a 53 kDa recombinant protein whose concentration was determined by a standard protein
assay (per the manufacture). The molar concentration of rLTIP
was calculated from multiple quantitative Western blots with
varying concentrations of Positope and rLTIP using anti-HisG
monoclonal antibody (Invitrogen). Subsequently, in the same
manner but using anti-LTIP Western blots, calibrated rLTIP was
used to determine the LTIP content of plasma pooled from four
normolipidemic subjects. Using a molecular weight of 17,425
for the protein portion of LTIP (18), a final concentration was
assigned. This standard pool was divided into aliquots and stored
at 280jC.

Clinical samples
All plasma specimens were obtained from subjects who
enrolled in GeneBank, a large (n 5 ?10,000) and wellcharacterized tissue repository from subjects undergoing elective
diagnostic left heart catheterization. Coronary vessel stenosis was
reported on a scale of 0–2, where 0 5 normal, 1 5 diffuse,
moderate (,50% stenosis), and 2 5 .50% stenosis for the most
affected vessel. In all groups, the vessel stenosis score was greater
in males than in females and averaged .1.7, except for
normolipidemic (1.20) and hypercholesterolemic (1.42)
females. Plasma samples used in this study were from individuals
with no reported renal disease, acute hepatitis, or history of
cirrhosis and normal creatinine values. Diabetes was an exclusion
criterion for hyperlipidemic subjects. Furthermore, normolipidemic subjects taking lipid-lowering medication were excluded to
eliminate the possibility that some hyperlipidemic subjects fall
in the normolipidemic range as a result of pharmacologic intervention. All GeneBank participants gave written informed

consent, and the Institutional Review Board of the Cleveland
Clinic approved the study protocol. Plasma was isolated from
fasting whole blood collected in EDTA tubes. Samples were
maintained at 4jC immediately after phlebotomy, processed
within 4 h of blood draw, and stored at 280jC until use.
Lipoprotein/lipid measurements were performed as described
previously (19). Samples were randomized and assayed for LTIP
content as described above and for CETP mass by a commercially
available ELISA kit (Wako Diagnostics, Richmond, VA).

RESULTS
Characterization of anti-LTIP antibody
Rabbit anti-LTIP raised against the recombinant bacterial LTIP-GST fusion protein recognized three proteins in
plasma, with molecular masses of 133, 34.5, and 29.2 kDa
(Fig. 1A). Preimmune rabbit serum or mouse anti-GST
detected none of these three plasma bands, whereas two
bands, of molecular masses consistent with albumin and
IgG heavy chain, were detected on all blots. The two lower
molecular mass immunoreactive bands in plasma bracketed the single band (31.7 kDa) detected in partially
purified LTIP. Upon ultracentrifugation at d 5 1.21 to
remove plasma lipoproteins, the 133 kDa protein was
quantitatively recovered in the lipoprotein-free fraction,
whereas the lower immunoreactive bands were recovered
in the lipoprotein-containing fraction (Fig. 1B). Although
the identity of the 133 kDa band is unknown, it appears
unlikely that this band contains LTIP, because this band is
not detected with previously described (3) anti-LTIP
peptide antibodies (unpublished observations).
LTIP is heavily glycosylated, resulting in an aberrantly
high molecular mass on SDS-PAGE gels compared with
its core protein of ?17.4 kDa (3, 18). We considered that
the two low molecular mass immunoreactive bands in
plasma might be LTIP with different carbohydrate con-

Fig. 1. Characterization of anti-lipid transfer inhibitor protein (LTIP) antibody. A: Western blot of antiLTIP, preimmune serum (PI), or anti-glutathione S-transferase (GST) antibody against human plasma
(lane 1) and partially purified LTIP (lane 2). B: Western blot of anti-LTIP reactivity with plasma (lane 1) and
the d , 1.21 g/ml (lane 2) and d . 1.21 g/ml (lane 3) density fractions of human plasma. C: Anti-LTIP
Western blot of plasma incubated without (lane 1) or with N-acetylneuraminidase (NANase) (lane 2) (1 ml of
plasma 6 10 mU of NANase) and partially purified LTIP incubated without (lane 3) or with NANase (6 mg of
LTIP 6 10 mU of NANase) (lane 4). D: Western blot of partially purified LTIP (lane 1) or recombinant LTIP
(lane 2) with anti-LTIP and anti-HisG antibodies. Samples were electrophoresed on 7.5% polyacrylamide
gels in A–C and on 4–20% gels in D. LTIP has a lower apparent molecular mass on gradient gels. Values of
the molecular mass markers shown are in kDa.
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tent. When plasma was treated with NANase to remove
sialic acid residues, these two bands persisted but shifted
?3 kDa smaller (Fig. 1C). However, treatment of partially
purified LTIP with this enzyme yielded two proteins that
comigrated with the bands present in enzyme-treated
plasma (Fig. 1C). These results indicate that differences in
Western blot band patterns between plasma and partially
purified LTIP are accounted for by differences in sialic
acid content. We conclude that both low molecular mass
immunoreactive bands in plasma are LTIP. Additional
proof that the immunoreactive band(s) detected with this
antibody are LTIP was obtained with recombinant LTIP
isolated from baculovirus-infected Sf21 insect cells. AntiLTIP reacted with partially purified rLTIP, revealing a
molecular mass similar to that for plasma-derived LTIP
(Fig. 1D). Identification of this band as rLTIP is based on
coreactivity with anti-HisG, the epitope tag in this construct.
With partially purified LTIP, we further examined its
carbohydrate content and evaluated the consequences of
carbohydrate removal on LTIP activity. When treated with
NANase, there was a small but significant (P , 0.03)
reduction in LTIP activity (Fig. 2). Treatment with
NANase followed by removal of serine/threonine-linked
carbohydrate chains with O-glycanase markedly suppressed LTIP activity. Treatment with these two enzymes
also resulted in the production of a single LTIP band with
a molecular mass of ?20 kDa, slightly larger than the
expected size for the protein core of LTIP (Fig. 2, inset).
This suggests that the single predicted N-glycosylation site

Fig. 2. Effects of enzymatic deglycosylation on LTIP activity. Partially purified LTIP (40 mg) was treated with NANase (20 mU, 1 h
at 37jC) or NANase followed by O-glycanase (4 mU, 3 h at 37jC),
and then LTIP activity was measured in a LDL-to-HDL lipid transfer
assay (see Methods). Values are means 6 SD of n 5 3 (control), n 5
4 (NANase), or n 5 2 (NANase 1 O-glycanase) replicates. Inset:
LTIP Western blot of treated samples. Electrophoresis was
performed on 4–20% gradient gels, resulting in lower apparent
molecular mass for native LTIP and poor resolution of the two bands
produced by NANase treatment compared with Fig. 1.
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at asparagine 103 might be occupied. Although treatment
of LTIP with N-glycanase had no effect on LTIP molecular
mass (data not shown), this negative result is not definitive
given that N-glycanase does not cleave all asparaginelinked carbohydrates. For LTIP contained in plasma,
NANase plus O-glycanase resulted in the complete loss of
the lower molecular mass form of LTIP and about half of
the upper band, concomitant with the appearance of a
single 20 kDa product, as seen with partially purified
LTIP (data not shown). Complete digestion of the upper
band has not been accomplished in the limited studies
performed. Like isolated LTIP, plasma LTIP was resistant
to N-glycanase.
Development of an LTIP ELISA
For LTIP quantitation by an ELISA, partially purified
LTIP was bound to microtiter plates and then reacted with
anti-LTIP in the presence or absence of competing soluble
antigen. Multiple variables were examined. Among the
most critical was establishing conditions for adequate
solubilization of LTIP contained in plasma. We examined
the effects of Tween-20 (0.1–2.0%), Nonidet P-40 (0.5%),
and Triton X-100 (0.1–0.5%) on the reactivity of LTIP in
plasma. Overall, Tween-20 was the most effective. However, low Tween-20 concentrations resulted in a flat response at higher plasma concentrations (low dilutions),
suggesting that Tween-20 concentrations of ,0.5% are not
adequate to solubilize plasma LTIP over the entire dose
range. Conversely, Tween-20 concentrations of >2%
tended to flatten the overall dose-response curve, indicating
that antigen-antibody interactions were being compromised. One percent Tween-20 was chosen because it
avoided both of these problems. Fresh and frozen/thawed
plasma behaved identically in the ELISA, showing that
freezing does not measurably alter LTIP immunoreactivity.
The specificity of the ELISA for LTIP is demonstrated in
Fig. 3. Despite containing different contaminating proteins, parallel response curves were obtained with plasma
and multiple chromatographic fractions obtained during
LTIP purification. The phenyl-Sepharose unbound fraction, which contained very little LTIP but high levels of the
133 kDa protein by Western blot (Fig. 1B), gave no response in the ELISA.
This configuration of the ELISA has been used in
multiple applications to quantify LTIP in plasma and
plasma fractions. However, when used to measure LTIP in
hyperlipidemic plasma, we observed that this detergent
treatment was not adequate when cholesterol or TG
concentrations were increased markedly, as shown by the
failure of different dilutions to yield similar values for
LTIP. We subsequently determined that the addition of
0.5% Nonidet P-40 to the 1% Tween-20 pretreatment step
was sufficient to overcome these effects without significantly affecting the shape or slope of the standard curve
generated with normolipidemic plasma. When plasma of
varying lipid contents was pretreated with this detergent
mixture, nearly parallel dose-response curves were observed (Fig. 4A). Only when plasma TG levels were very
high (400 mg/dl) did a slight shift in the dose-response

Fig. 3. ELISA for LTIP in plasma and plasma fractions. LTIP was
purified from plasma as described in Methods. Then, plasma was
chemically delipidated, yielding lipoprotein-deficient (Lp-def.)
plasma. Lipoprotein-deficient plasma was applied to phenylSepharose, resulting in an unbound fraction (Phenyl unbound)
and an eluted fraction containing LTIP (Phenyl LTIP). This
fraction was subsequently applied to carboxymethyl-cellulose, and
LTIP was eluted (CM LTIP). Samples were diluted as indicated and
assayed for LTIP by ELISA. Values are means of triplicate determinations. B/Bo, where B 5 binding of anti-LTIP in the presence of sample (competitor) and Bo 5 binding of anti-LTIP in the
absence of competitor.

curve occur. Typically, the ELISA was log-linear for
normolipidemic plasma dilutions from 5- to 80-fold,
which corresponds to 49–778 ng of LTIP per well (0.97–
15.56 mg LTIP/ml). A representative standard curve
generated with pooled normolipidemic plasma is shown
in Fig. 4B. Under these final conditions, the interassay and
intra-assay coefficients of variance were 7.6% and 6.8%,
respectively. Typically, unknown plasma samples were diluted 20-fold for analysis.
LTIP in plasma from subjects with normal and
high lipid levels
The lipid and lipoprotein levels of study subjects are
shown in Table 1. Among the four study groups, there
were no differences in subject age. Within a study group,
male and female groups were comparable in mean lipid
and lipoprotein levels except for hypertriglyceridemic

subjects, in which group males tended to have lower total
cholesterol levels (212%) and consequently lower LDL
(223%) and HDL (216%) cholesterol levels. Males with
combined hypercholesterolemia and hypertriglyceridemia
had a slightly lower mean age compared with females in
this group. The use of lipid-lowering drugs was common
for hyperlipidemic subjects. Hormone replacement therapy was very low in normolipidemic females (2 of 42) and
moderate in hypercholesterolemic females (4 of 12),
hypertriglyceridemic females (4 of 10), and those with
increased plasma cholesterol and TG (3 of 12).
LTIP values for the study groups described in Table 1
are shown in Table 2. Among normolipidemic subjects,
males had significantly more LTIP than females. Up to
27% of normolipidemic subjects were diabetic, although
diabetes did not appear to have an effect on LTIP levels.
LTIP levels in nondiabetic versus diabetic normolipidemic
females were 73.8 versus 70.2 mg/ml, and in males these
values were 94.3 versus 98.6 mg/ml. The trend for higher
LTIP levels in normolipidemic males was also seen in
hypercholesterolemic subjects, but this difference did not
quite reach significance (P 5 0.06). In hypertriglyceridemic subjects, the converse was observed. Male hypertriglyceridemic subjects had markedly reduced LTIP
content, equivalent to only 56% of male normolipidemic
subjects. On the other hand, LTIP levels tended to
increase in females with high TG levels compared with
normolipidemic females, but these did not reach significance (P 5 0.065). LTIP levels in male versus female
hypertriglyceridemic subjects were highly significantly
different. Within a lipid phenotype, we did not observe
any significant differences in LTIP values between those
taking versus not taking lipid-lowering medications. In
contrast to the observations for LTIP, there were no
differences in CETP levels for males versus females in any
lipid phenotype group or between lipid phenotypes.
CETP tended to be higher in groups with high cholesterol,
but this did not reach significance.
In addition to normolipidemic subjects and hypertriglyceridemic subjects (TG . 200 mg/dl), we also examined
whether the changes in LTIP noted between these two
groups also existed in individuals with mildly increased
TG levels (150 , TG , 200 mg/dl). In males in whom

Fig. 4. ELISA response to plasma LTIP in samples
treated with Tween-20 and Nonidet P-40. A: LTIP
dose-response curves for plasma from hypercholesterolemic (hyper TC; plasma cholesterol 5
223 mg/dl), hypertriglyceridemic [hyper TG; plasma
triglyceride (TG) 5 400 mg/dl], combined hypercholesterolemic/hypertriglyceridemic (hyper
TC1TG; cholesterol 5 203 mg/dl, TG 5 212 mg/
dl), and normolipidemic (normo.) subjects. B: A
representative standard curve generated with the
normolipidemic standard plasma pool. Values are
means 6 SD (n 5 3). B/Bo, where B 5 binding of
anti-LTIP in the presence of sample (competitor)
and Bo 5 binding of anti-LTIP in the absence
of competitor.
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TABLE 1. Patient population statistics
Lipid Phenotype

Group

No.

Age

TC

Total
Female
Male
Total
Female
Male
Total
Female
Male
Total

76
42
34
25
12
13
25
10
15
25

65.1 6
64.0 6
66.5 6
64.1 6
67.4 6
61.2 6
62.0 6
62.8 6
61.4 6
64.7 6

Female
Male

12
13

70.0 6 3.3
60.2 6 3.0d

years
Normolipidemic
Hypercholesterolemic
Hypertriglyceridemic
Combined hypercholesterolemic 1
hypertriglyceridemic

1.5
2.1
2.1
2.6
4.3
3.1
2.1
3.2
2.9
2.4

HDL
Cholesterol

TG

Percentage
L-l Rxa

Percentage
Diabeticb

2.7
3.2
4.4
5.1
6.1
7.6
3.4
4.4
4.3d
8.0

0
0
0
28
50
8
84
80
87
44

21
17
27
0
0
0
0
0
0
0

143.9 6 9.9
154.8 6 11.9

58
31

0
0

LDL
Cholesterol

mg/dl
160
165
154
228
225
230
168
181
160
248

63
64
65
65
65
68
64
66
6 4c
68

252 6 11
244 6 13

93
91
94
127
128
126
301
285
311
357

63
64
65
6 10
6 14
6 15
6 18
6 20
6 27
6 36

403 6 64
315 6 35

44.8
46.0
43.4
52.0
56.9
47.5
36.0
41.8
32.1
39.4

6
6
6
6
6
6
6
6
6
6

1.4
2.1
1.8
3.2
4.9
3.9
1.9
2.8
2.0c
1.8

42.0 6 2.8
37.1 6 2.3

96.7 6
100.7 6
91.7 6
150.3 6
142.2 6
157.7 6
78.3 6
86.1 6
72.4 6
150.2 6

TC, total cholesterol; TG, triglyceride. Patients were categorized as follows: normolipidemic, TC < 200 mg/dl, TG < 150 mg/dl; hypercholesterolemic, TC . 200 mg/dl, TG < 200 mg/dl; hypertriglyceridemic, TC < 200 mg/dl, TG . 200 mg/dl; combined hypercholesterolemic 1
hypertriglyceridemic, TC . 200 mg/dl, TG . 200 mg/dl. Values are means 6 SEM.
a
L-l Rx, percentage of study subjects taking lipid-lowering medications.
b
Percentage of study subjects who are diabetic. All such subjects were actively taking insulin and/or oral hypoglycemic medications.
c
P , 0.01 (male vs. female of the same lipid phenotype).
d
P , 0.05 (male vs. female of the same lipid phenotype).

hypertriglyceridemia resulted in markedly reduced LTIP
levels, there was a tendency toward reduced LTIP levels
in mildly hypertriglyceridemic subjects (Fig. 5), although
this trend was not significant. In contrast, like that seen
in female hypertriglyceridemic subjects, even a modest
increase in plasma TG in females was associated with
higher LTIP levels (P 5 0.038) (Fig. 5). When data for all
females with increased TG were combined (i.e., those with
TG . 150 mg/dl), there was a highly significant increase
in LTIP levels compared with normolipidemic females
(P , 0.01). Together, these data indicate that increased
plasma TG levels result in marked, but opposite, effects on
LTIP levels in male and female subjects.
Within a given lipid group, correlation analysis did not
reveal any statistically significant associations between LTIP
levels and subject age, plasma cholesterol or TG concentration, LDL or HDL cholesterol level, or the ratio of LDL
to HDL. When male and female subjects were evaluated
separately, the only demonstrable correlation was between
LTIP and HDL cholesterol levels in male subjects with

normal lipid levels (Fig. 6). HDL levels were positively
correlated with LTIP levels. As would be expected, CETP
levels were significantly and positively associated with plasma
cholesterol levels in normolipidemic (r 5 0.311, P 5 0.007)
and in combined normolipidemic/hypercholesterolemic
(r 5 0.264, P 5 0.008) groups.

DISCUSSION
We report here the development of a quantitative assay
for LTIP in human plasma that uses partially purified LTIP
bound to the solid phase. By Western blot, we observed
that LTIP exists as two molecular mass forms. Removal of
sialic acids shifted both bands to lower molecular mass,
whereas O-glycanase treatment converted these two forms
to a single protein band still larger than that predicted for
carbohydrate-free LTIP. Differences in the band pattern
between plasma LTIP and partially purified LTIP could be
explained by variances in sialic acid content, suggesting

TABLE 2. LTIP and CETP levels in the study populations
LTIP
Lipid Phenotype

All Subjects

Normolipidemic
Hypercholesterolemic
Hypertriglyceridemic
Combined hypercholesterolemic + hypertriglyceridemic

83.5
89.5
70.0
79.1

CETP

Male

Female

All Subjects

lg/ml
6 4.8
6 7.6
6 6.3
6 8.4

96.1 6 8.2a
102.8 6 10.7
53.4 6 4.8b,c
83.7 6 14.9

73.2 6
75.0 6
94.9 6
74.1 6

5.1
9.3
9.8
7.6

1.71 6 0.06
1.87 6 0.10
1.55 6 0.12
1.99 6 0.24

CETP, cholesteryl ester transfer protein; LTIP, lipid transfer inhibitor protein. Patients were categorized into lipid phenotypes as described in
Table 1. Plasma was diluted 1:20 into buffer containing 1% Tween-20 and 0.5% Nonidet P-40 and incubated overnight, and then LTIP was quantified
by ELISA. Plasma CETP was measured by a commercially available immunoassay. Values are means 6 SEM. Group sizes are given in Table 1.
a
P , 0.02 (normolipidemic males vs. females).
b
P , 0.0001 (hypertriglyceridemic vs. normolipidemic males).
c
P , 0.0005 (hypertriglyceridemic males vs. females).
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Fig. 5. Variation in LTIP mass as a function of plasma TG. LTIP
levels are shown for normocholesterolemic subjects with normal
(,150 mg/dl), moderately increased (150–200 mg/dl), and high
(.200 mg/dl) TG. Values are means 6 SEM. Numbers of male
and female subjects with moderately increased TG were 16 and
7, respectively. Other group sizes are shown in Table 1.

that there is a loss of some sialic acid during purification.
Enzymatic removal of sialic acid from LTIP resulted in a
very small change in LTIP activity, suggesting that the
conformation of LTIP is not altered significantly by the
removal of these charged carbohydrate groups, and
further indicating that the immunoreactivity of partially
purified LTIP and native plasma LTIP is not likely to be
different. Thus, like CETP, variable glycosylation results in
the presence of two plasma forms of LTIP. Unlike CETP,
in which this variation is accounted for by the presence or
absence of N-linked carbohydrate on asparagine 341 (20),
LTIP forms arise from variable O-linked carbohydrate
content. Variable glycosylation of CETP alters its specific
activity; whether this also occurs with LTIP is unknown.

Fig. 6. Correlation of plasma LTIP levels in normocholesterolemic males with HDL cholesterol levels. Data are for males with
normal cholesterol levels and TG , 200 mg/dl (i.e., normal 1
moderately increased TG). r 5 0.422, P 5 0.0023.

The presence of two LTIP-sized bands in plasma was
surprising because we previously observed a single band
(11), which comigrated with the lower of the two bands
detected here, when blots were developed with antibodies
raised against LTIP peptides (designated F1 and F2) (3).
This is likely explained by the presence of carbohydrate
chains on these peptide sequences in natural LTIP, which
reduces antibody recognition of these peptides. For
example, the sequence for peptide antibody F1 contains
two of three predicted O-linked mucin-type carbohydrate
sites, and the sequence for peptide antibody F2 contains the
sole predicted N-linked carbohydrate site. We suggest that
the upper LTIP band in plasma, which appears to be the
most extensively glycosylated form based on our enzymatic
studies, is a poor substrate for these peptide antibodies.
We determined here that LTIP levels in normolipidemic subjects are similar to the 70 mg/ml estimate we
calculated previously (3), but considerably higher than the
27 mg/ml value estimated by others using an electroimmunoassay (21). To calibrate the ELISA, we used an
alternative approach that is based on comparative immunoreactivities of insect cell-derived rLTIP with a known
protein containing the same epitope tag and, subsequently, of this calibrated rLTIP standard with a plasma
pool. This approach was taken because of our inability to
produce sufficient pure LTIP or rLTIP that could have
served as a primary standard. However, we believe this
approach to be valid for several reasons. First, rLTIP and
the reference protein, Positope, contain the identical
HisG epitope that is recognized by a commercially available monoclonal antibody. Both proteins also contain a
second tag, Xpress, and Western blots with anti-Xpress
monoclonal antibody reported a very similar quantitative
relationship between these two proteins. Second, although insect-derived rLTIP lacks sialic acid residues, removal of these groups from plasma LTIP did not alter
its immunoreactivity and had little effect on its activity.
However, other glycosylation of rLTIP, which dramatically
alters LTIP immunoreactivity and activity, appears intact
because this rLTIP displays the same anomalous behavior
as plasma LTIP by 7.5% SDS-PAGE (i.e., shows an apparent molecular mass ?10–12 kDa larger than expected)
and its inhibitory specific activity is similar to that of
plasma-derived LTIP (data not shown).
Little is known about the variability of LTIP levels in
normolipidemic and hyperlipidemic individuals. Previously, we observed in a small group of hyperlipidemic
subjects (all hypercholesterolemic, some hypertriglyceridemic) that LTIP activity is increased by 3-fold over that
in normolipidemic subjects (11). Additionally, within this
group, there was a strong negative correlation between
LTIP activity and plasma TG levels. These trends were
substantiated by changes in LTIP immunoreactivity, as
detected on Western blots of plasma using an anti-LTIP
peptide antiserum (11). Here, we have reexamined these
relationships in a larger number of subjects with more
discrete lipid abnormalities.
In normolipidemic subjects, LTIP averaged 83.5 mg/ml,
indicating that LTIP (apolipoprotein F) has a plasma conLipid transfer inhibitor protein levels
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centration similar to that of apolipoproteins C-I, C-III, D,
and E (22). We report for the first time that LTIP mass is
higher in male versus female normolipidemic subjects.
Whether these differences exist in a younger adult population remains to be examined. Among normolipidemic
males, we observed a significant positive correlation between LTIP levels and HDL cholesterol. This association is
consistent with the proposed role of LTIP in regulating
lipid flux among lipoproteins in normolipidemic subjects.
That is, not only does high LTIP reduce lipid transfer to
LDL, it also inhibits CE transfer from HDL2, which could
result in a net increase in HDL cholesterol levels even
though CE transfer out of HDL3 is stimulated (9, 10).
Our previously reported marked increase in LTIP in
hypercholesterolemic subjects (11) was not substantiated
here in hypercholesterolemic subjects with or without
hypertriglyceridemia. A possible explanation is that in the
previous study, plasma cholesterol levels in the study
subjects ranged from 203 to 314 mg/dl, whereas here the
range was only from 201 to 238 mg/dl. Thus, with this mild
hypercholesterolemia, changes in LTIP may be too small
to detect. Alternatively, because we did not find a correlation between LTIP and plasma cholesterol levels in the
earlier study, it is possible that increased LTIP levels occur
only at higher plasma cholesterol levels. The fact that we
also failed to see an increase in CETP in hypercholesterolemic subjects, as has been commonly reported, is consistent with the initial suggestion above that the magnitude
of hypercholesterolemia in this study group may simply
be too low to detect significant effects on LTIP or CETP.
In contrast to the foregoing, we did observe a correlation between LTIP and plasma TG levels, as noted before
(11), but the effect was unique for each gender. In males,
we found that hypertriglyceridemia was associated with a
marked reduction in LTIP levels. Among normolipidemic
and hypertriglyceridemic male subjects, there was a
significant negative correlation between LTIP and plasma
TG (r 5 20.406, P 5 0.005). We previously suggested that
this negative correlation may be attributable to the
redistribution of LTIP from LDL to VLDL, resulting in
increased plasma clearance of LTIP when TG levels are
increased (11). Contrary to that found in males, we were
surprised to find in females that LTIP levels tended to
increase in hypertriglyceridemia. Even females with
moderate increases in TG showed increased LTIP. The
mechanisms underlying this gender difference are unclear, but it does not appear to result from an effect of
hormone replacement therapy in this older female population, because only a minority of subjects received
such treatment and there was no difference between LTIP
levels in hypertriglyceridemic females receiving versus
not receiving therapy.
In conclusion, we show that LTIP levels are different
in normolipidemic males and females. We also provide
strong evidence of an association between LTIP levels and
plasma TG levels, suggesting a link with VLDL metabolism.
Notably, this correlation of LTIP and plasma TG was
opposite for males and females. We also show that CETP
and LTIP have different responses to changes in plasma
134
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lipid levels, resulting in unique changes in the LTIP/
CETP ratio in various dyslipidemic conditions, especially
hypertriglyceridemia. As suggested by in vitro studies (10,
23), changes in the relative amounts of CETP and LTIP
will likely have marked effects on the flux of lipids between lipoproteins. Defining the consequences of altered
LTIP/CETP ratios on lipoprotein composition and metabolism is important, especially as we anticipate the development of pharmacologic approaches to decrease levels
of functional CETP.
This research was supported by Grant HL-60934 from the National Heart, Lung, and Blood Institute, National Institutes of Health.
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